Metraipolis › archive › dc_715d88a080f0

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/28548467
DOI
10.22034/apjcp.2017.18.4.1151
License (as archived)
solo-consultazione
Archived
2026-11-09T12:13:03.517Z
SHA-256 of the archived text
eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd
Stable URL of this page
https://metraipolis.com/documento/dc_715d88a080f0

How to cite

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467 — Europe PMC (en), https://europepmc.org/article/MED/28548467 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_715d88a080f0 (Metraipolis archive dc_715d88a080f0, sha256 eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd)
BibTeX
@misc{dc715d88a080f0,
  title = {Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer — Europe PMC PMID:28548467},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/28548467},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_715d88a080f0; sha256 eb46d622ce1d92107377bdfa3f1c587e7f66e27c458d7ade496483bb53e2e8bd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/28548467. Agents can read the archived copy with the MCP tool read_document.